Clinical Trial Update: Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sintilimab combined with regorafenib and cetuximab for advanced colorectal cancer (mCRC) with intermediate status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Regorafenib (regorafenib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Sintilimab, Cetuximab, Regorafenib,Combine,mCRC | Phase 2 | Status: UNKNOWN